N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: Synergistic antitumor activity with arabinofuranosylcytosine
Thomas Szekeres(Medical University of Vienna), Philipp Saiko(Ludwig Boltzmann Institute Applied Diagnostics), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Walter Jaeger(University of Vienna), Sibylle Madlener(Comprehensive Cancer Center Vienna), Michael Grusch(Comprehensive Cancer Center Vienna), Astrid Bernhaus(Vienna General Hospital), Mária Ozsvár-Kozma(Medical University of Vienna), Thomas Erker(University of Vienna), Norbert Handler(University of Vienna), Andreas Lackner(Medical University of Vienna), Geraldine Graser(Medical University of Vienna), Monika Fritzer‐Szekeres(Vienna General Hospital), Margit Jaschke(Vienna General Hospital), Georg Krupitza(Medical University of Vienna)
Cited by 23
Related Papers
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
|PLoS ONE|2011|437
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
|Nature Medicine|2022|395
Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure–activity relationship
|Biochemical Pharmacology|2005|303